5 Supplements Women Are Looking at During Perimenopause in 2026

Perimenopause is not a single health experience, and the supplement market is increasingly reflecting that reality. Sleep disruption, fluctuating mood, changes in body composition, reduced exercise recovery, and long-term bone and cardiovascular concerns may appear within the same life stage, but they do not necessarily require the same nutritional strategy.

That shift is helping drive interest in personalized supplement stacks rather than one generic “menopause formula.” Menopause-related supplement launches increased 17% globally from 2021 to 2026, according to the market statistic currently cited across industry discussions. Public reporting from Nutrition Insight also confirms substantial growth in products carrying menopause-related claims, although reported percentages vary by dataset and time frame.

For women over 40, the most relevant question is not which formula is universally best. The more useful question is which ingredients align with a specific nutritional objective, existing diet, lifestyle, lab results, and medication profile. The following five ingredients are receiving particular attention in 2026 and offer practical opportunities for brands developing targeted perimenopause products.

> Important note: Supplements should complement, not replace, qualified medical care. A healthcare professional should be consulted before beginning a new regimen, particularly when pregnancy is possible, chronic conditions are present, or prescription medication is being used.

1. Magnesium, Especially Glycinate

Magnesium remains one of the most frequently considered supplements for women navigating perimenopause because it intersects with several common wellness priorities, including sleep, muscle function, relaxation, and normal energy metabolism.

Magnesium glycinate, also called magnesium bisglycinate, is attracting attention because its chelated structure is generally considered gentle on the digestive system compared with forms that are more likely to produce a laxative effect. However, the form should not be treated as a guarantee of superior outcomes. The appropriate selection depends on the intended product positioning, dosage, sensory characteristics, stability, and target consumer.

The National Institutes of Health Office of Dietary Supplements lists a recommended dietary allowance of 310–320 milligrams per day for adult women, depending on age. The tolerable upper intake level for magnesium from supplements and medications is 350 milligrams per day, excluding magnesium obtained from food and water.

For consumers, a magnesium product may be most compelling when positioned around a clearly defined use case rather than broad hormonal promises. A bedtime powder, capsule, or combination product could be designed for evening routines, while a lower-dose daily formula may be more appropriate for general nutritional support.

Brands should also account for potential interactions with certain antibiotics, osteoporosis medications, and thyroid treatments. Clear labeling, measured serving sizes, and responsible structure-function language are essential.

2. Creatine Monohydrate for Strength, Recovery, and Healthy Aging

Creatine has moved well beyond its traditional association with bodybuilding. In 2026, women are increasingly evaluating creatine monohydrate for strength training, exercise performance, muscle maintenance, and healthy aging.

This interest is particularly relevant during and after the menopausal transition, when changes in estrogen levels may coincide with alterations in body composition, recovery, and musculoskeletal resilience. Creatine is not a hormone and should not be marketed as a treatment for menopause symptoms. Its most defensible positioning relates to the phosphocreatine system, which helps support rapid energy production during high-intensity activity.

The International Society of Sports Nutrition position stand identifies creatine monohydrate as the most extensively studied form. A common maintenance protocol is 3–5 grams per day. A loading phase of approximately 20 grams per day for five to seven days, divided into smaller servings, is optional rather than essential.

Recent research also continues to examine creatine’s possible effects on cognition, mental fatigue, and mood. The evidence is promising but not conclusive, particularly for broad cognitive outcomes. Brands should therefore avoid overstating claims such as “eliminates brain fog” or “balances hormones.”

From a product-development perspective, creatine can support several formats: unflavored powder, flavored stick packs, capsules, and gummies. Powder remains technically efficient for delivering a full daily serving, while gummies may improve convenience but can introduce challenges related to serving size, sugar content, texture, moisture control, and cost.

3. Adaptogens, Including Ashwagandha

Adaptogens are being incorporated into more targeted perimenopause concepts, particularly products designed around stress management, sleep routines, and perceived resilience. Ashwagandha is among the most prominent ingredients in this category.

Some short-term studies suggest that specific ashwagandha preparations may support stress management and sleep quality. The evidence is preparation-specific, meaning that results from one standardized root extract cannot automatically be applied to every powder, extract, or proprietary blend.

The National Center for Complementary and Integrative Health states that ashwagandha may be safe for short-term use of up to approximately three months, while long-term safety remains uncertain. Reported concerns include possible liver injury, thyroid effects, digestive upset, and interactions with sedatives, immunosuppressants, diabetes medications, blood-pressure medications, and thyroid hormone treatments.

These considerations make ashwagandha a strong example of why targeted formulation requires more than trend analysis. Standardized extract specifications, botanical identity testing, contaminant screening, dosage transparency, and appropriate warnings should be established before commercialization. Pregnancy, breastfeeding, thyroid disorders, autoimmune conditions, liver concerns, and upcoming surgery warrant particular caution.

For brands, an adaptogen product may be better positioned as part of a carefully explained stress-and-sleep concept than as a universal menopause solution.

4. Omega-3 EPA and DHA

Omega-3 fatty acids continue to occupy a foundational position in women’s wellness. EPA and DHA are being considered for products supporting normal cardiovascular function, brain health, and dietary balance, while their broader relevance becomes more apparent as consumers take a longer-term view of the menopausal transition.

The NIH Office of Dietary Supplements omega-3 fact sheet distinguishes between ALA, found primarily in plant foods, and the long-chain omega-3s EPA and DHA, commonly sourced from fish oil or algae. There is no established RDA specifically for EPA or DHA, so product design should focus on transparent disclosure of the actual EPA and DHA amounts rather than relying only on total fish-oil weight.

Ingredient quality is central to this category. Brands should evaluate oxidation control, sensory performance, source verification, allergen considerations, sustainability documentation, and packaging that protects the oil from light and oxygen. Algal DHA may provide a useful option for plant-focused or vegetarian product lines.

Omega-3 products also require responsible communication. Consumers using anticoagulant or antiplatelet medication should discuss supplementation with a qualified professional, particularly at higher intakes. Claims should remain within permitted structure-function boundaries and should not imply prevention or treatment of cardiovascular disease.

5. Vitamin D3 with K2

Vitamin D3 paired with vitamin K2 is receiving attention as a bone-health-focused concept for women over 40. The rationale is understandable: bone health becomes a more prominent consideration as estrogen-related protection changes during the menopausal transition.

The NIH vitamin D fact sheet identifies an adult recommended dietary allowance of 600 IU per day, or 15 micrograms, for adults through age 70, increasing to 800 IU per day after age 70. The adult upper limit is 4,000 IU per day, unless higher intake is medically supervised.

Vitamin K2, particularly the MK-7 form, is frequently included in commercial formulas, although vitamin K does not have a separate universally established RDA based on the K2 form. Product developers should avoid suggesting that the combination guarantees improved bone density or prevents osteoporosis. Bone-health messaging should be supported by appropriate education about calcium intake, resistance exercise, vitamin D status, and clinical screening.

Vitamin K can interfere with warfarin and other anticoagulation protocols. This interaction should be addressed through label review and consumer education.

Building a Personalized Perimenopause Stack

The strongest product opportunity may not be a five-ingredient formula containing every popular trend. It may be a coordinated product ecosystem in which each product serves a distinct purpose:

• Magnesium glycinate for an evening wellness routine
• Creatine monohydrate for strength and active aging
• A standardized adaptogen formula for stress-focused positioning
• Omega-3 EPA/DHA for foundational nutritional support
• Vitamin D3 with carefully considered K2 for bone-health education

This structure allows consumers to select based on individual priorities while enabling brands to develop complementary products, starter bundles, subscription pathways, and educational content without forcing every customer into one oversized serving.

For companies entering this category, SolisLabs’ custom formulation and product development services can support ingredient sourcing, formulation refinement, artwork coordination, manufacturing, packaging, and labeling. Its supplement manufacturing capabilities are designed for brands seeking an end-to-end development process through a USA-based, GMP-certified facility.

A credible perimenopause product line should be built around objective criteria: ingredient identity, dosage rationale, evidence quality, stability, testing, label compliance, and consumer safety. Trust, security, and accessibility remain essential at every stage, from the initial formulation brief to the finished product.

The personalized stack trend is likely to continue as women seek more specific and flexible approaches to wellness after age 40. The most durable brands will be those that treat this audience as informed decision-makers, communicate evidence with precision, and develop products that are practical, transparent, and appropriately scoped. Selection of any individual supplement remains a strictly individual prerogative and is best evaluated with qualified professional guidance.